Navigation Links
AcelRx Pharmaceuticals Hires Mark Evashenk as Vice President of Clinical Operations
Date:3/6/2009

REDWOOD CITY, Calif., March 6 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. announced today it has hired Mark Evashenk as Vice President, Clinical Operations. In this new position, Mr. Evashenk will assist in defining developmental strategy, guiding clinical protocol design and study conduct, and managing risk assessment. He will report to Dr. Pamela Palmer, the company's Chief Medical Officer. "We are very fortunate to continue to attract leaders in the pharmaceutical industry; Mark possesses an unparalleled breadth and depth of experience that will be of great value to AcelRx," stated Dr. Palmer. "Mark will play a vital role in overseeing all phases of clinical development, with a particular emphasis on the successful execution of studies planned for our mid- and late-stage product candidates."

Mark has over 25 years of pharmaceutical and device development experience with a focus on project management and clinical operations, most recently as Director of Clinical Operations at ALZA Corporation, a Johnson & Johnson Company. Throughout his career, Mark has managed clinical operations teams for numerous studies worldwide representing all stages of development, including registration studies supporting four successful NDA filings. Mark holds his BS in Environmental Toxicology from UC Davis.

About AcelRx Pharmaceuticals, Inc.

AcelRx Pharmaceuticals is a privately held pharmaceutical company dedicated to the development and commercialization of new therapies for the treatment of pain and other conditions where there is an unmet need for improved safety and efficacy. The company applies its proprietary dosage form and delivery technologies to enhance the safety, therapeutic benefit and commercial attractiveness of currently approved compounds.

For additional information about AcelRx Pharmaceuticals visit http://www.acelrx.com.


'/>"/>
SOURCE AcelRx Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. AcelRx Pharmaceuticals Reports Positive Results From a Phase 2 Clinical Trial of Sublingual Sufentanil NanoTabs(TM) in Treating Post-Operative Pain
2. AcelRx Pharmaceuticals Hires Roman Skowronski, M.D., Ph.D. as Vice President of Clinical Development
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
7. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
8. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
9. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
10. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
11. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Audacity, a leading California-based health and ... the Huntsworth Health Group, is proud to announce the ... her role, Gonzales will serve as Senior Vice President ... to welcome a talent of Jamie’s caliber to the ... “She is a proven healthcare innovation leader and brand ...
(Date:12/17/2014)... , Dec. 17, 2014  United Therapeutics Corporation (NASDAQ: ... promotions as well as changes to Martine Rothblatt ... Promotions United Therapeutics announced the promotion ... Co-Chief Executive Officer and David Zaccardelli , Pharm.D. ... connection with these promotions, Dr. Rothblatt,s title will change ...
(Date:12/17/2014)... Dec. 17, 2014 Tigercat Pharma, Inc. ... study evaluating the investigational oral NK-1 receptor antagonist ... severe, chronic itch who are unresponsive or inadequately ... topical steroids and antihistamines. The ... Analog Scale (VAS) itch score from baseline, comparing ...
(Date:12/15/2014)... 2014 METTLER TOLEDO is pleased ... ParticleView V19 with PVM technology , is ... vision and measurement tool continuously captures high-resolution images ... V19 then automatically prepares a report pairing the ... and concentration changes. This compelling blend of high ...
Breaking Biology Technology:Audacity Welcomes Healthcare Communications Expert Jamie Gonzales as Senior Vice President of Client Services 2United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 2United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 3United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 4Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4New Real-Time In Situ Probe-Based Video Microscope from METTLER TOLEDO 2
... WA, and VANCOUVER, Oct. 9 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, ... Cormack, president and chief executive officer of OncoGenex, has ... The Year(R). The Ernst & Young Entrepreneur Of The ... entrepreneurs that are building successful, dynamic businesses. , "I ...
... ... Supersaturation Assessment and Control for the Development and Optimization of Crystallization Processes, a method ... for the production and control of qualitative supersaturation trajectories. , ... (PRWEB) October 9, 2009 -- The quantitative ...
... , ... is announcing its 2010 Best Practices awards program and is opening the call for ... of technology and strategic innovation--initiatives and collaborations that manifestly improve some facet of the ... ...
Cached Biology Technology:OncoGenex Pharmaceuticals CEO Named Canada's Pacific Ernst & Young's Entrepreneur Of The Year(R) in the Health Sciences Category 2OncoGenex Pharmaceuticals CEO Named Canada's Pacific Ernst & Young's Entrepreneur Of The Year(R) in the Health Sciences Category 3Calibration Free Supersaturation Assessment and Control for the Development and Optimization of Crystallization Processes 2The 2010 Bio-IT World Best Practices Call for Entries has been Released -- Highlight your Company's Excellence in Innovation 2The 2010 Bio-IT World Best Practices Call for Entries has been Released -- Highlight your Company's Excellence in Innovation 3
(Date:12/10/2014)... Research and Markets ( http://www.researchandmarkets.com/research/xclcvw/biometrics_market ... "Biometrics Market in Japan 2014-2018" report to ... The integration of biometrics and ... and upgradation of the driver,s license is one ... Besides the aforementioned projects, biometrics is being used ...
(Date:12/4/2014)... , Dec. 3, 2014  Crossmatch™, a ... announced that its DigitalPersona ® Pro Enterprise ... have been deployed throughout First Bank branch locations ... South Carolina and Virginia. First Bank, ... Southern Pines, North Carolina , selected ...
(Date:11/21/2014)... 2014  Earlier this year Donald Spector , ... one of the most prolific inventors in the world, ... from Smartphones to third party agencies. Spector envisioned this ... of the earliest known patents in this area. Now ... military, child care, elder care and hospital applications. This ...
Breaking Biology News(10 mins):Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4
... Two scientists from Cold Spring Harbor Laboratory (CSHL) are ... genetic mutation that causes Joubert Syndrome. JBTS, as it ... that is very rare in the general population but ... The study was published in collaboration with Dor Yeshorim, ...
... crops relies on a relatively stable climate, not dramatic ... evolutionary, ecological, genetic and agronomic considerations, Dr. Shahal Abbo, ... Hebrew University of Jerusalem, Israel, and colleagues, demonstrate why ... domestication in the Near East. Rather, the variety of ...
... COLUMBIA, Md. , Jan. 12 Cylex Incorporated® ... Panel approved the creation of new CPT coding based on ... the fact that existing CPT codes insufficiently captured all steps ... , In an effort to keep customers informed of these ...
Cached Biology News:CSHL scientists use next-gen sequencing to rapidly discover genetic cause of devastating disorder 2Stable climate and plant domestication linked 2Cylex(TM) Awarded New CPT Code For Its ImmuKnow(R) Assay 2Cylex(TM) Awarded New CPT Code For Its ImmuKnow(R) Assay 3
... is the simplest, easiest-to-use system ever for ... handling capabilities,into their labs, or groups in ... applications on a separate instrument. Plate-handling is ... even when you have thousands of samples., ...
Cells are grown in triple flasks, roller bottles, or NUNC Factory. Viability and growth curves are generated from a parallel representative culture....
NovaScreen offers cell biology, cell culture and molecular biology services for companies who lack a cell culture facility....
... Affinity Life Sciences provides cost effective cell ... proteins or monoclonal antibodies. Quality at a ... whether you require research or commercial product, ... production methods such as roller bottles, hollow ...
Biology Products: